keyword
MENU ▼
Read by QxMD icon Read
search

irinotecan

keyword
https://www.readbyqxmd.com/read/29156610/bevacizumab-for-patients-with-recurrent-multifocal-glioblastomas
#1
Michael C Burger, Stella Breuer, Hans C Cieplik, Patrick N Harter, Kea Franz, Oliver Bähr, Joachim P Steinbach
In patients with glioblastoma, antiangiogenic therapy with bevacizumab (BEV) has been shown to improve progression-free survival (PFS), but not overall survival (OS). Especially in patients with an unusual infiltrative phenotype as seen in multifocal glioblastoma, the use of BEV therapy is still more controversial. Therefore, we prepared a retrospective case series with 16 patients suffering from a multifocal glioblastoma treated with BEV. We compared these patients to a matched control cohort of 16 patients suffering from glioblastoma with a single lesion treated with BEV...
November 20, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29151523/neuroendocrine-carcinoma-of-the-stomach-a-response-to-combination-chemotherapy-consisting-of-ramucirumab-plus-paclitaxel
#2
Yuki Matsubara, Takayuki Ando, Ayumu Hosokawa, Hiroshi Mihara, Hiroaki Takagi, Naokatsu Nakata, Hiroki Yoshita, Sohachi Nanjo, Shinya Kajiura, Haruka Fujinami, Toshiro Sugiyama
Extrapulmonary neuroendocrine carcinoma (NEC) is a rare disease, and there is no standard chemotherapy. A 73-year-old man was diagnosed with advanced gastric NEC. He received chemotherapy of irinotecan plus cisplatin, and amrubicin monotherapy. After failure of second-line chemotherapy, he received ramucirumab plus paclitaxel; this treatment was chosen because vascular endothelial growth factor 2 was strongly expressed in the tumor endothelial cells. After two cycles, his NEC had markedly reduced in size, and he continued with this treatment for over eight months...
November 20, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29146538/rational-design-of-polysorbate-80-stabilized-human-serum-albumin-nanoparticles-tailored-for-high-drug-loading-and-entrapment-of-irinotecan
#3
Neetika Taneja, Kamalinder K Singh
Human serum albumin (HSA) nanoparticles are considered to be versatile carrier of anticancer agents in efficiently delivering the drug to the tumor site without causing any toxicity. The aim of the study was to develop stable HSA nanoparticles (NPs) of drug irinotecan (Iro) having slightly water solubility and moderate HSA binding. A novel strategy of employing a hydrophilic non-ionic surfactant polysorbate 80 which forms protein-polysorbate 80 complex with increased affinity and improvement in Iro-HSA binding has been used to maximize the loading and entrapment efficiency of Iro in HSA-NPs...
November 13, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29142750/evaluation-of-epidermal-growth-factor-receptor-serum-levels-and-their-association-with-clinicopathological-characteristics-in-patients-with-colorectal-cancer
#4
Mehmet Karabulut, Cigdem Usul Afsar, Halil Alıs, Ebru Oran, Senem Karabulut, Cevher Akarsu, Nuri Alper Sahbaz, Alpen Yahya Gümüsoglu, Elif Bilgin, Nuri Faruk Aykan
Colorectal cancer (CRC) is a major public health concern and one of the leading causes of cancer-related mortality worldwide. The aim of the present study was to determine the serum epidermal growth factor receptor (sEGFR) levels in healthy volunteers and patients with CRC, to determine the association between tumor marker levels and clinicopathological findings, and investigate its prognostic value. A total of 140 patients with CRC were enrolled in the present study. Pre-treatment sEGFR levels were determined using ELISA...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29138948/correction-to-s-1-and-irinotecan-plus-bevacizumab-as-second-line-chemotherapy-for-patients-with-oxaliplatin-refractory-metastatic-colorectal-cancer-a-multicenter-phase-ii-study-in-japan-kscc1102
#5
Yuji Miyamoto, Akihito Tsuji, Hiroaki Tanioka, Soichiro Maekawa, Hirofumi Kawanaka, Masaki Kitazono, Eiji Oki, Yasunori Emi, Hidetsugu Murakami, Yutaka Ogata, Hiroshi Saeki, Mototsugu Shimokawa, Shoji Natsugoe, Yoshito Akagi, Hideo Baba, Yoshihiko Maehara
In the original publication, in Abstract, the sentence that reads as, "Oral S-1 at a dose of 80 mg/m(2) was…………. drug-free interval" should read as, "Oral S-1 at a dose of 40 mg/m(2) was administered twice daily for 2 weeks, followed by a 1-week drug-free interval.
November 14, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29138869/cepharanthine-exhibits-a-potent-anticancer-activity-in-p53-mutated-colorectal-cancer-cells-through-upregulation-of-p21waf1-cip1
#6
Arkornnut Rattanawong, Vilawan Payon, Wacharee Limpanasittikul, Chatikorn Boonkrai, Apiwat Mutirangura, Piyanuch Wonganan
Cepharanthine (CEP), a biscoclurine alkaloid isolated from Stephania cepharantha Hayata, has demonstrated anticancer activity in several different types of cancer cells. Colorectal cancer (CRC) is one of the most common cancers in both men and women. Mutated p53 in CRC was reported to be associated with resistance to commonly used chemotherapeutic agents including, 5‑fluorouracil, oxaliplatin and irinotecan. Many studies reported that mutation of p53 induced chemoresistance through several mechanisms, including induction of drug efflux, disruption of cell cycle regulation, evasion of apoptosis and upregulation of DNA repair...
November 9, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29137301/antitumor-efficacy-of-triple-monoclonal-antibody-inhibition-of-epidermal-growth-factor-receptor-egfr-with-mm151-in-egfr-dependent-and-in-cetuximab-resistant-human-colorectal-cancer-cells
#7
Stefania Napolitano, Giulia Martini, Erika Martinelli, Carminia Maria Della Corte, Floriana Morgillo, Valentina Belli, Claudia Cardone, Nunzia Matrone, Fortunato Ciardiello, Teresa Troiani
Purpose: We investigated the effect of triple monoclonal antibody inhibition of EGFR to overcome acquired resistance to first generation of anti-EGFR inhibitors. Experimental design: MM151 is a mixture of three different monoclonal IgG1 antibodies directed toward three different, non-overlapping, epitopes of the EGFR. We performed an in vivo study by using human CRC cell lines (SW48, LIM 1215 and CACO2) which are sensitive to EGFR inhibitors, in order to evaluate the activity of MM151 as compared to standard anti-EGFR mAbs, such as cetuximab, as single agent or in a sequential strategy of combination MM151 with irinotecan (induction therapy) followed by MM151 with a selective MEK1/2 inhibitor (MEKi) (maintenance therapy)...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29137221/anti-pancreatic-cancer-activity-of-onc212-involves-the-unfolded-protein-response-upr-and-is-reduced-by-igf1-r-and-grp78-bip
#8
Avital Lev, Amriti R Lulla, Jessica Wagner, Marie D Ralff, Joshua B Kiehl, Yan Zhou, Cyril H Benes, Varun V Prabhu, Wolfgang Oster, Igor Astsaturov, David T Dicker, Wafik S El-Deiry
Pancreatic cancer is chemo-resistant and metastasizes early with an overall five-year survival of ∼8.2%. First-in-class imipridone ONC201 is a small molecule in clinical trials with anti-cancer activity. ONC212, a fluorinated-ONC201 analogue, shows preclinical efficacy in melanoma and hepatocellular-cancer models. We investigated efficacy of ONC201 and ONC212 against pancreatic cancer cell lines (N=16 including 9 PDX-cell lines). We demonstrate ONC212 efficacy in 4 in-vivo models including ONC201-resistant tumors...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29134439/treatment-related-survival-associations-of-claudin-2-expression-in-fibroblasts-of-colorectal-cancer
#9
Artur Mezheyeuski, Carina Strell, Ina Hrynchyk, Tormod Kyrre Guren, Anca Dragomir, Tatyana Doroshenko, Oksana Pashkova, Julia Gorgun, Kseniya Ruksha, Per Pfeiffer, Elin H Kure, Halfdan Sorbye, David Edler, Anna Martling, Bengt Glimelius, Arne Östman, Anna Portyanko
Claudin-2 is a trans-membrane protein-component of tight junctions in epithelial cells. Elevated claudin-2 expression has been reported in colorectal cancer (CRC). The aim of this study was to investigate the expression patterns of claudin-2 in human CRC samples and analyze its association with clinical characteristics and treatment outcome. TMAs of primary tumors from two cohorts of metastatic CRC (mCRC) were used. Claudin-2 IHC staining was evaluated in a semi-quantitative manner in different regions and cell types...
November 13, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29133623/immu-140-a-novel-sn-38-antibody-drug-conjugate-targeting-hla-dr-mediates-dual-cytotoxic-effects-in-hematological-cancers-and-malignant-melanoma
#10
Thomas M Cardillo, Serengulam V Govindan, Maria B Zalath, Diane L Rossi, Yang Wang, Chien-Hsing Chang, David M Goldenberg
HLA-DR is a member of the MHC class II antigen family expressed on hematological and solid tumors.  Antibodies directed against HLA-DR have demonstrated some clinical success, but toxicities limited development.  IMMU-140 is an anti-HLA-DR antibody-drug conjugate comprised of the active metabolite of irinotecan, SN-38, conjugated to a humanized anti-HLA-DR IgG4 antibody (IMMU-114); the IgG4 naked antibody is devoid of immune functions. Our aim was to determine if SN-38, the metabolite of a drug not commonly used in hematopoietic cancers, would be effective and safe when targeted to HLA-DR-expressing tumors...
November 13, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29131533/a-phase-i-ii-pharmacokinetics-pharmacodynamics-study-of-irinotecan-combined-with-s-1-for-recurrent-metastatic-breast-cancer-in-patients-with-selected-ugt1a1-genotypes-the-jbcrg-m01-study
#11
Hiroshi Ishiguro, Shigehira Saji, Shogo Nomura, Sunao Tanaka, Takayuki Ueno, Masahide Onoue, Hiroji Iwata, Takeharu Yamanaka, Yasutsuna Sasaki, Masakazu Toi
S-1 and irinotecan combination is attractive for breast cancer refractory to anthracyclines and taxanes. Patients with advanced human epidermal growth factor receptor 2 (HER2)-negative breast cancer previously treated with anthracyclines and taxanes were eligible. Patients with brain metastases and homozygous for UGT1A1 *6 or *28 or compound heterozygous (*6/*28) were excluded. A dose-escalation design was chosen for the phase I portion (level 1: irinotecan 80 mg/m(2)  days 1-8 and S-1 80 mg/m(2)  days 1-14 every 3 weeks; level 2: irinotecan 100 mg/m(2) and S-1 80 mg/m(2) )...
November 13, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29129089/systemic-therapy-for-esophageal-cancer-chemotherapy
#12
Geoffrey Y Ku
As one-half of patients with esophagogastric cancer (EGC) present with metastatic disease and the majority of patients with locally advanced disease will eventually develop metastatic disease despite multimodality therapy, most patients will receive palliative chemotherapy at some point. The reference first-line regimen consists of a fluoropyrimidine/platinum combination, which is the standard in East Asia, where this disease is endemic. Options include infusional 5-fluorouracil (5-FU), capecitabine, S-1 and other oral 5-FU pro-drugs and cisplatin or oxaliplatin...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29125991/effects-of-quercetin-combined-with-anticancer-drugs-on-metastasis-associated-factors-of-gastric-cancer-cells-in-vitro-and-in-vivo-studies
#13
Cing-Syuan Lei, Yu-Chen Hou, Man-Hui Pai, Ming-Tsan Lin, Sung-Ling Yeh
Chemotherapy is essential to most patients with gastric cancer and the anticancer drug, irinotecan (CPT-11), and its metabolite, SN-38, an inhibitor of DNA topoisomerase I, are first-line chemotherapies for gastric cancer. Quercetin, a flavonoid that is widely found in various vegetables and fruits, has the ability to potentiate the efficacy of anticancer drugs. The purpose of this study was to investigate the therapeutic effect of quercetin combined with irinotecan/SN-38 in the AGS human gastric cancer cell line in vitro and in vivo...
September 28, 2017: Journal of Nutritional Biochemistry
https://www.readbyqxmd.com/read/29124328/efficacy-of-combination-chemotherapy-using-irinotecan-and-nedaplatin-for-patients-with-recurrent-and-refractory-endometrial-carcinomas-preliminary-analysis-and-literature-review
#14
Morikazu Miyamoto, Masashi Takano, Mika Kuwahara, Hiroaki Soyama, Kento Kato, Hiroko Matuura, Takahiro Sakamoto, Kazuki Takasaki, Tadashi Aoyama, Tomoyuki Yoshikawa, Kenichi Furuya
PURPOSE: We aimed to retrospectively evaluate the efficacy and toxicity of an irinotecan hydrochloride (CPT) and nedaplatin (N) combination therapy for recurrent and refractory endometrial carcinoma, administered based on UGT1A1 genotype. METHODS: Between 2009 and 2017, 21 patients who received CPT-N therapy for recurrent endometrial carcinoma as second- or third-line chemotherapy at our hospital were identified. The CPT-N regimen included 40-70 mg/m(2) of CPT-11 on days 1, 8, and 15, and 50 mg/m(2) of nedaplatin on day 1, q4 weeks...
November 9, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29121274/quality-of-life-in-the-glarius-trial-randomizing-bevacizumab-irinotecan-versus-temozolomide-in-newly-diagnosed-mgmt-nonmethylated-glioblastoma
#15
Niklas Schäfer, Martin Proescholdt, Joachim P Steinbach, Astrid Weyerbrock, Peter Hau, Oliver Grauer, Roland Goldbrunner, Franziska Friedrich, Veit Rohde, Florian Ringel, Uwe Schlegel, Michael Sabel, Michael W Ronellenfitsch, Martin Uhl, Stefan Grau, Mathias Hänel, Oliver Schnell, Dietmar Krex, Peter Vajkoczy, Ghazaleh Tabatabai, Frederic Mack, Christina Schaub, Theophilos Tzaridis, Michael Nießen, Sied Kebir, Barbara Leutgeb, Horst Urbach, Claus Belka, Walter Stummer, Martin Glas, Ulrich Herrlinger
Background: The GLARIUS trial which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) as compared to standard temozolomide (TMZ) in the first-line therapy of MGMT-nonmethylated glioblastoma showed that progression-free survival was significantly prolonged by BEV/IRI while overall survival was similar in both arms. The present report focusses on quality of life (QoL) and Karnofsky performance score (KPS) during the whole course of the disease. Patients and methods: Patients (n=170) received standard radiotherapy and were randomized (2:1) for BEV/IRI or standard TMZ...
November 7, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29118308/synthesis-molecular-docking-and-biological-evaluation-of-quinolone-derivatives-as-novel-anticancer-agents
#16
Jie Li, Tu-Cai Zheng, Yi Jin, Jian-Guo Xu, Jian-Gang Yu, Yan-Wen Lv
A series of novel quinolone derivatives (8a-j) were synthesized, and their anticancer activities were tested in human cancer cell lines A549, HL-60, and Hela. Compound 8i was found to be 5-times more potent in cell-killing activity for cell lines A549, HL-60, and Hela than the positive control irinotecan or cisplatin, with IC50 of 0.009, 0.008 and 0.010 μM, respectively. The docking study revealed that compound 8i might have strong interactions with the active site of DNA-Topoisomerase I.
November 9, 2017: Chemical & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/29116379/phase-ii-study-of-nedaplatin-and-irinotecan-as-adjuvant-chemotherapy-for-completely-resected-non-small-cell-lung-cancer
#17
Shuji Murakami, Haruhiro Saito, Tetsuro Kondo, Hiroyuki Ito, Fumihiro Oshita, Kouzo Yamada
INTRODUCTION: Cisplatin-based chemotherapy is the standard adjuvant therapy for patients with completely resected stage II or III non-small cell lung cancer (NSCLC). However, the completion rate of four cycles of cisplatin-based chemotherapy is about 50%. This phase II study was conducted to evaluate the tolerability and efficacy of nedaplatin and irinotecan as adjuvant chemotherapy. METHODS: Patients with pathological stage II or III NSCLC who underwent complete resection were enrolled...
November 7, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29113730/conversion-to-resection-in-patients-receiving-systemic-chemotherapy-for-unresectable-and-or-metastatic-colorectal-cancer-predictive-factors-and-prognosis
#18
Hiroaki Nozawa, Soichiro Ishihara, Kazushige Kawai, Keisuke Hata, Tomomichi Kiyomatsu, Toshiaki Tanaka, Takeshi Nishikawa, Kensuke Otani, Koji Yasuda, Kazuhito Sasaki, Manabu Kaneko, Koji Murono
BACKGROUND: Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases remain largely unknown. PATIENTS AND METHODS: We reviewed the data from metastatic CRC (mCRC) patients who had received oxaliplatin- or irinotecan-based systemic chemotherapy from 2005 to 2016...
October 19, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29113721/prognostic-factors-and-optimal-therapy-for-stages-i-ii-neuroendocrine-carcinomas-of-the-uterine-cervix-a-multi-center-retrospective-study
#19
Mitsuya Ishikawa, Takahiro Kasamatsu, Hitoshi Tsuda, Masaharu Fukunaga, Atsuhiko Sakamoto, Tsunehisa Kaku, Toru Nakanishi, Yoko Hasumi, Takashi Iwata, Tsukasa Baba, Takayoshi Nogawa, Wataru Kudaka, Hiroshi Kaneda, Shigemitsu Ono, Fumitaka Saito, Yoshimi Taniguchi, Satoshi Okada, Mika Mizuno, Takashi Onda, Nobuo Yaegashi
PURPOSE: We aimed to determine appropriate treatment guidelines for patients with stages I-II high-grade neuroendocrine carcinomas (HGNEC) of the uterine cervix in a multicenter retrospective study. PATIENTS AND METHODS: We reviewed the clinicopathological features and prognoses of 93 patients with HGNEC of International Federation of Gynecology and Obstetrics (FIGO) stages I and II. All patients were diagnosed with HGNEC by central pathological review. RESULTS: The median overall survival (OS) and disease-free survival (DFS) were 111...
November 4, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/29113244/impact-of-the-individualization-of-the-first-line-chemotherapy-for-advanced-colorectal-cancer-based-on-collagen-gel-droplet-embedded-drug-sensitivity-test
#20
Takumi Ochiai, Kazuhiko Nishimura, Tomoo Watanabe, Masayuki Kitajima, Akinori Nakatani, Kiichi Nagayasu, Shigetoshi Naito, Tsuyoshi Sato, Kenji Kishine, Yu Abe, Chihiro Hara, Susumu Yamada, Satomi Mashiko, Isao Nagaoka
Leucovorin (FOL) and fluorouracil (5-FU) plus oxaliplatin (l-OHP; FOLFOX) or FOL and 5-FU plus irinotecan (SN-38; FOLFIRI) are widely used as first-line chemotherapy regimens in the treatment of advanced colorectal cancer (CRC). However, second-line chemotherapy must be abandoned in certain cases due to disease progression, adverse effects or high medical cost. Therefore, the most effective regimen should be selected as first-line chemotherapy. We reported that individualization of first-line treatment (FOLFOX/FOLFIRI/Dual/Poor responder) was possible using the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) and that individualized first-line chemotherapy with CD-DST may improve the prognosis of patients with unresectable CRC...
November 2017: Oncology Letters
keyword
keyword
21455
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"